NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Vancouver, B.C. – September 8, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FFE:
6UF) (“NeonMind'' or the “Company”), an integrated drug development and wellness company focused
on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions,
today announced that Robert Tessarolo, President and Chief Executive Officer, will participate in the
H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually starting Monday,
September 13, 2021 at 7:00 a.m. ET.
H.C. Wainwright 23rd Annual Global Investment Conference Details:
Date: September 13-15, 2021
Registration: www.hcwevents.com/annualconference
The Company’s presentation will be available on-demand at the start of the conference. In addition to
the Company’s presentation, management will be available to participate in one-on-one meetings with
investors who are registered to attend the conference.
For more information regarding the conference or to schedule a one-on-one meeting with
management, please contact KCSA Strategic Communications at [email protected] or your H.C.
Wainwright representatives directly.
About NeonMind Biosciences Inc.
NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness
products to address obesity and weight management conditions and to promote health and wellness.
The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of
psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical
services division focused on launching specialty mental health clinics that integrate psychedelic
therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that
currently sells mushroom-infused products to promote health and wellness.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs
targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the
serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The
Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C
receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-branded
specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to
address a variety of mental health needs.
NeonMind’s consumer division currently sells NeonMind-branded coffee products in the United States
and Canada through NeonMind’s direct to consumer e-commerce platform.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
For further information, please contact:
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein / Tim Regan
Tel: 212-896-1210
Media Inquiries:
KCSA Strategic Communications
Annie Graf
Tel: 786-390-2644
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news
release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These
statements relate to future events or NeonMind’s future performance. The use of any of the words
“could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements
relating to matters that are not historical facts are intended to identify forward-looking information and
are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future
events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its
ability to retain key personnel, and its expectation as to the development of its intellectual property and
other steps in its preclinical and clinical drug development constitute forward-looking information. Actual
results and developments may differ materially from those contemplated by forward-looking
information. Readers are cautioned not to place undue reliance on forward-looking information. The
statements made in this press release are made as of the date hereof. NeonMind disclaims any intention
or obligation to publicly update or revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as may be expressly required by applicable securities
laws.